Cargando…

The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity

The role of lipids in modulating membrane protein function is an emerging and rapidly growing area of research. The rational design of lipids that target membrane proteins for the treatment of pathological conditions is a novel extension in this field and provides a step forward in our understanding...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Katie A., Mostyn, Shannon N., Frangos, Zachary J., Shimmon, Susan, Rawling, Tristan, Vandenberg, Robert J., O’Mara, Megan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949037/
https://www.ncbi.nlm.nih.gov/pubmed/33450225
http://dx.doi.org/10.1016/j.jbc.2021.100282
_version_ 1783663477168013312
author Wilson, Katie A.
Mostyn, Shannon N.
Frangos, Zachary J.
Shimmon, Susan
Rawling, Tristan
Vandenberg, Robert J.
O’Mara, Megan L.
author_facet Wilson, Katie A.
Mostyn, Shannon N.
Frangos, Zachary J.
Shimmon, Susan
Rawling, Tristan
Vandenberg, Robert J.
O’Mara, Megan L.
author_sort Wilson, Katie A.
collection PubMed
description The role of lipids in modulating membrane protein function is an emerging and rapidly growing area of research. The rational design of lipids that target membrane proteins for the treatment of pathological conditions is a novel extension in this field and provides a step forward in our understanding of membrane transporters. Bioactive lipids show considerable promise as analgesics for the treatment of chronic pain and bind to a high-affinity allosteric-binding site on the human glycine transporter 2 (GlyT2 or SLC6A5). Here, we use a combination of medicinal chemistry, electrophysiology, and computational modeling to develop a rational structure–activity relationship for lipid inhibitors and demonstrate the key role of the lipid tail interactions for GlyT2 inhibition. Specifically, we examine how lipid inhibitor head group stereochemistry, tail length, and double-bond position promote enhanced inhibition. Overall, the l-stereoisomer is generally a better inhibitor than the d-stereoisomer, longer tail length correlates with greater potency, and the position of the double bond influences the activity of the inhibitor. We propose that the binding of the lipid inhibitor deep into the allosteric-binding pocket is critical for inhibition. Furthermore, this provides insight into the mechanism of inhibition of GlyT2 and highlights how lipids can modulate the activity of membrane proteins by binding to cavities between helices. The principles identified in this work have broader implications for the development of a larger class of compounds that could target SLC6 transporters for disease treatment.
format Online
Article
Text
id pubmed-7949037
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-79490372021-03-19 The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity Wilson, Katie A. Mostyn, Shannon N. Frangos, Zachary J. Shimmon, Susan Rawling, Tristan Vandenberg, Robert J. O’Mara, Megan L. J Biol Chem Research Article The role of lipids in modulating membrane protein function is an emerging and rapidly growing area of research. The rational design of lipids that target membrane proteins for the treatment of pathological conditions is a novel extension in this field and provides a step forward in our understanding of membrane transporters. Bioactive lipids show considerable promise as analgesics for the treatment of chronic pain and bind to a high-affinity allosteric-binding site on the human glycine transporter 2 (GlyT2 or SLC6A5). Here, we use a combination of medicinal chemistry, electrophysiology, and computational modeling to develop a rational structure–activity relationship for lipid inhibitors and demonstrate the key role of the lipid tail interactions for GlyT2 inhibition. Specifically, we examine how lipid inhibitor head group stereochemistry, tail length, and double-bond position promote enhanced inhibition. Overall, the l-stereoisomer is generally a better inhibitor than the d-stereoisomer, longer tail length correlates with greater potency, and the position of the double bond influences the activity of the inhibitor. We propose that the binding of the lipid inhibitor deep into the allosteric-binding pocket is critical for inhibition. Furthermore, this provides insight into the mechanism of inhibition of GlyT2 and highlights how lipids can modulate the activity of membrane proteins by binding to cavities between helices. The principles identified in this work have broader implications for the development of a larger class of compounds that could target SLC6 transporters for disease treatment. American Society for Biochemistry and Molecular Biology 2021-01-12 /pmc/articles/PMC7949037/ /pubmed/33450225 http://dx.doi.org/10.1016/j.jbc.2021.100282 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Wilson, Katie A.
Mostyn, Shannon N.
Frangos, Zachary J.
Shimmon, Susan
Rawling, Tristan
Vandenberg, Robert J.
O’Mara, Megan L.
The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity
title The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity
title_full The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity
title_fullStr The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity
title_full_unstemmed The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity
title_short The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity
title_sort allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949037/
https://www.ncbi.nlm.nih.gov/pubmed/33450225
http://dx.doi.org/10.1016/j.jbc.2021.100282
work_keys_str_mv AT wilsonkatiea theallostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT mostynshannonn theallostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT frangoszacharyj theallostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT shimmonsusan theallostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT rawlingtristan theallostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT vandenbergrobertj theallostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT omarameganl theallostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT wilsonkatiea allostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT mostynshannonn allostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT frangoszacharyj allostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT shimmonsusan allostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT rawlingtristan allostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT vandenbergrobertj allostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity
AT omarameganl allostericinhibitionofglycinetransporter2bybioactivelipidanalgesicsiscontrolledbypenetrationintoadeeplipidcavity